Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05681624 · ClinicalTrials.gov registry record · NA

Maternal Oxygen Supplementation for Intrauterine Resuscitation

A NA study of Fetal Hypoxia and Fetal Distress, sponsored by Washington University School of Medicine.

Recruiting
Registry status
NA
Development phase
2,124
Enrollment target
1
Study location

NCT05681624 is a NA study of Fetal Hypoxia and Fetal Distress that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 2,124 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05681624, a NA study of Fetal Hypoxia and Fetal Distress, is actively recruiting participants, sponsored by Washington University School of Medicine.

RECRUITING
Registry status
NA
Development phase
2,124 participants
Enrollment target
1
Study location

Study Summary

More than 80% of the 3 million women who labor and deliver each year in the United States undergo continuous electronic fetal monitoring (EFM) during labor in order to fetal hypoxia and prevent the transition to acidemia, expedited operative delivery, and/or neonatal morbidity. Category II EFM is the most commonly observed group of fetal heart rate features in labor. One common response to Category II EFM is maternal oxygen (O2) supplementation. The theoretic rationale for O2 administration is that it increases O2 transfer to a hypoxic fetus. There are conflicting national guidelines regarding O2 administration - the American College of Obstetricians and Gynecologists suggest O2 is ineffective, whereas the Association of Women's Health, Obstetric, and Neonatal Nurses recommend continued use given lack of definitive data on safety and efficacy. A recent national survey of nearly 600 Labor \& Delivery providers in February 2022 revealed that 49% still use O2 . Thus, there remains equipoise on the topic and high-quality data on the safety of intrapartum O2 is needed. None of the trials to date have studied the effect of intrapartum O2 on important clinical measures of neonatal or maternal morbidity. This safety data is imperative because the field of obstetrics must hold supplemental O2 to the same rigorous standards applied to any drug used in pregnancy. Without data on these definitive outcomes, it will be challenging to implement evidence-based recommendations for supplemental O2 use on Labor \& Delivery. The investigators will conduct a large, multicenter, randomized noninferiority trial of O2 supplementation versus room air in patients with Category II EFM in labor.

Interventions

  • OTHER Maternal oxygen supplementation
  • OTHER Room air

Study Locations (1)

Missouri

  • Barnes Jewish Hospital - St Louis

Trial Details

FieldValue
Enrollment Target 2,124 participants
Start Date 2023-05-22
Est. Completion 2028-12-31
Phase NA

What the Registry Record Tells You About NCT05681624

The ClinicalTrials.gov registry entry for NCT05681624 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 2,124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Fetal Hypoxia appearing as the primary indexed condition, and to 2 interventions - of which Maternal oxygen supplementation is the first listed.

NCT05681624 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT05681624 about?

NCT05681624 is a clinical study titled "Maternal Oxygen Supplementation for Intrauterine Resuscitation". More than 80% of the 3 million women who labor and deliver each year in the United States undergo continuous electronic fetal monitoring (EFM) during labor in order to fetal hypoxia and prevent the transition to acidemia, expedited operative delivery, and/or neonatal morbidity. Category II EFM is th...

What is the current status of trial NCT05681624?

This trial is currently recruiting. It is a NA study. The enrollment target is 2,124 participants. The study started on 2023-05-22. Estimated completion is 2028-12-31.

What conditions does trial NCT05681624 study?

This clinical trial studies the following conditions: Fetal Hypoxia, Fetal Distress, Labor and Delivery Complication.

What interventions are being tested in trial NCT05681624?

The interventions under investigation include: Maternal oxygen supplementation (OTHER), Room air (OTHER).

Who is sponsoring clinical trial NCT05681624?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05681624 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fetal Hypoxia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.